Neuro-Oncological Ventral Antigen 1 (NOVA1) (N-Term) Peptid
Kurzübersicht für Neuro-Oncological Ventral Antigen 1 (NOVA1) (N-Term) Peptid (ABIN8106322)
Target
Spezies
Quelle
Applikation
-
-
Protein Region
- N-Term
-
Verwendungszweck
- NOVA1 Peptide - N-terminal region
-
Sequenz
- THTGVPIDLD PPDSRKRPLE APPEAGSTKR TNTGEDGQYF LKVLIPSYAA
-
-
Neuro-Oncological Ventral Antigen 1 (NOVA1) peptide
NOVA1 Reaktivität: Human Wirt: Synthetic BP, Imm
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
This is a synthetic peptide designed for use in combination with anti- NOVA1 Antibody (ARP90851_P050),. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 µL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Buffer
- Lyophilized powder
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20 °C. Avoid repeat freeze-thaw cycles.
-
-
- NOVA1 (Neuro-Oncological Ventral Antigen 1 (NOVA1))
-
Hintergrund
-
Background Information: Functions to regulate alternative splicing in neurons by binding pre-mRNA in a sequence-specific manner to activate exon inclusion. It binds specifically to the sequence UCAUY. Most likely acts to activate the inclusion of exon E3A in the glycine receptor alpha-2 chain and of exon E9 in gamma-aminobutyric-acid receptor gamma-2 subunit via a distal downstream UCAU-rich intronic splicing enhancer.
Alternative Symbols: Nova-1, G630039L02, 9430099M15Rik
-
Molekulargewicht
- 52 kDa
-
Gen-ID
- 664883
-
NCBI Accession
- NP_067336
-
UniProt
- Q9JKN6
Target
-
